Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the chemical formula C27H29N3O5 and a molecular weight of approximately 475.54 g/mol[6][8]. It is classified as an experimental drug and belongs to the class of organic compounds known as phenylalanine derivatives[2]. The structure features two phenylethylene groups, a hydroxy group, and a pyridine-containing carbamate moiety. There are no approved medical indications or clinical trial data available for this compound, and its mechanism of action has not been described in public databases. It appears in pharmaceutical research libraries such as ZINC15 but does not have evidence of development beyond early-stage research or screening[1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [1-(3-hydroxy-2-oxo-1-phenethyl-propylcarbamoyl)2-phenyl-ethyl]-carbamic acid pyridin-4-ylmethyl ester.